ClinicalTrials.gg
Biological

Lifileucel clinical trials

Also written LN-144.

studies test it
23
open now
11
in phase 3
1
first study started
2015

How each study uses lifileucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lifileucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Feb 2024 · AMTAGVI · BLA 125773 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lifileucel
7
Autologous TIL LN-144
2
Autologous Tumor Infiltrating Lymphocytes LN-144
2
Contego
2

Development codes

LN-144
4
LN-145
1

In one entry with another drug

Given together, or one or the other

Autologous Tumor Infiltrating Lymphocytes
7
LN-145
6

Studies by the year they started

22 studies that test it; most in 2026 (4); 1 more planned to start later

Studies that test lifileucel, by start year
YearStudies
20151
20172
20181
20191
20202
20211
20223
20233
20243
20251
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
9
Phase 2
12
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 11

Iovance Biotherapeutics, Inc. (10) · Memorial Sloan Kettering Cancer Center (2) · Vastra Gotaland Region (2) · Shanghai Juncell Therapeutics (2) · Richard Wu (1) · University of Kansas Medical Center (1) · Abramson Cancer Center at Penn Medicine (1) · Karam Khaddour, MD, MS (1)

Often tested with

Tested in the same studies.

Autologous Tumor Infiltrating Lymphocytes LN-145 (12) · Interleukin-2 (2) · Autologous Tumor Infiltrating Lymphocytes LN-145-S1 (2) · Melphalan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Lifileucel is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 4

Studies that test lifileucel.

Studies

Open first, then newest update. How each study uses lifileucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test lifileucel →

Given beside what is tested · 1 — lifileucel is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with lifileucel

Codes

What other systems call lifileucel · ClinicalTrials.gg INT017737

  • UNII (FDA) R0835E18NHLIFILEUCELOne source FDA
  • NCI Thesaurus C120552LifileucelOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.